Cardiomyopathy laboratory findings: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
{{Cardiomyopathy}} | {{Cardiomyopathy}} | ||
==Overview== | ==Overview== | ||
Hyponatremia can be seen in patients with cardiomypathy and other causes of HF: it has prognostic implications; as it indicates the activation of the | [[Hyponatremia]] can be seen in patients with cardiomypathy and other causes of [[HF]]: it has prognostic implications; as it indicates the activation of the [[renin-angiotensin system]] in response to the stress of the cardiomyopathy and/or [[heart failure]]. Kidney function could be affected as a result of medication-toxicity, volume depletion in cases of excessive [[diuresis]], or development of [[cardiorenal syndrome]]. [[Brain natriuretic peptide|Brain natriuretic peptide (BNP)]] is usually elevated in systolic heart dysfunction: it can also be falsely elevated in [[renal failure]] and [[pulmonary embolism]]. On the other hand, it can be falsely low in obese patients. | ||
==Cardiomyopathy Laboratory Findings== | ==Cardiomyopathy Laboratory Findings== | ||
* Hyponatremia can be seen in patients with cardiomypathy and other causes of HF: it has prognostic implications; as it indicates the activation of the | * [[Hyponatremia]] can be seen in patients with cardiomypathy and other causes of HF: it has prognostic implications; as it indicates the activation of the [[renin-angiotensin system]] in response to the stress of the cardiomyopathy and/or heart failure.<ref name="pmid24976920">{{cite journal |vauthors=Sisakian H |title=Cardiomyopathies: Evolution of pathogenesis concepts and potential for new therapies |journal=World J Cardiol |volume=6 |issue=6 |pages=478–94 |date=June 2014 |pmid=24976920 |doi=10.4330/wjc.v6.i6.478 |url=}}</ref> | ||
* Kidney function could be affected as a result of medication-toxicity, volume depletion in cases of excessive diuresis, or development of cardiorenal syndrome.<ref name="pmid24976920">{{cite journal |vauthors=Sisakian H |title=Cardiomyopathies: Evolution of pathogenesis concepts and potential for new therapies |journal=World J Cardiol |volume=6 |issue=6 |pages=478–94 |date=June 2014 |pmid=24976920 |doi=10.4330/wjc.v6.i6.478 |url=}}</ref> | * Kidney function could be affected as a result of medication-toxicity, volume depletion in cases of excessive [[diuresis]], or development of [[cardiorenal syndrome]].<ref name="pmid24976920">{{cite journal |vauthors=Sisakian H |title=Cardiomyopathies: Evolution of pathogenesis concepts and potential for new therapies |journal=World J Cardiol |volume=6 |issue=6 |pages=478–94 |date=June 2014 |pmid=24976920 |doi=10.4330/wjc.v6.i6.478 |url=}}</ref> | ||
* Brain natriuretic peptide (BNP) is usually elevated in systolic heart dysfunction: it can also be falsely elevated in renal failure and pulmonary embolism. On the other hand, it can be falsely low in obese patients. | * [[Brain natriuretic peptide|Brain natriuretic peptide (BNP)]] is usually elevated in systolic heart dysfunction: it can also be falsely elevated in renal failure and pulmonary embolism. On the other hand, it can be falsely low in obese patients. | ||
* Elevated troponin levels indicate ischemic heart disease, and should be investigated as much, till coronary arterial disease is ruled out. | * Elevated [[troponin]] levels indicate [[ischemic heart disease]], and should be investigated as much, till coronary arterial disease is ruled out. | ||
* Elevated iron saturation and ferritin are indicative of hemochromatosis as a cause of cardiomyopathy. | * Elevated iron saturation and [[ferritin]] are indicative of [[hemochromatosis]] as a cause of cardiomyopathy. | ||
==References== | ==References== | ||
| Line 21: | Line 21: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Revision as of 16:05, 31 December 2018
|
Cardiomyopathy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Guidelines |
|
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy |
|
Case Studies |
|
Cardiomyopathy laboratory findings On the Web |
|
American Roentgen Ray Society Images of Cardiomyopathy laboratory findings |
|
Risk calculators and risk factors for Cardiomyopathy laboratory findings |
Overview
Hyponatremia can be seen in patients with cardiomypathy and other causes of HF: it has prognostic implications; as it indicates the activation of the renin-angiotensin system in response to the stress of the cardiomyopathy and/or heart failure. Kidney function could be affected as a result of medication-toxicity, volume depletion in cases of excessive diuresis, or development of cardiorenal syndrome. Brain natriuretic peptide (BNP) is usually elevated in systolic heart dysfunction: it can also be falsely elevated in renal failure and pulmonary embolism. On the other hand, it can be falsely low in obese patients.
Cardiomyopathy Laboratory Findings
- Hyponatremia can be seen in patients with cardiomypathy and other causes of HF: it has prognostic implications; as it indicates the activation of the renin-angiotensin system in response to the stress of the cardiomyopathy and/or heart failure.[1]
- Kidney function could be affected as a result of medication-toxicity, volume depletion in cases of excessive diuresis, or development of cardiorenal syndrome.[1]
- Brain natriuretic peptide (BNP) is usually elevated in systolic heart dysfunction: it can also be falsely elevated in renal failure and pulmonary embolism. On the other hand, it can be falsely low in obese patients.
- Elevated troponin levels indicate ischemic heart disease, and should be investigated as much, till coronary arterial disease is ruled out.
- Elevated iron saturation and ferritin are indicative of hemochromatosis as a cause of cardiomyopathy.